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Context: Adrenal insufficiency (AI) is an important medical concern for clinicians when normocortisolemia is achieved during treatment of endogenous Cushing syndrome (CS).
Objective: To examine symptoms of potential AI in a large population of normocortisolemic patients
without CS treated with mifepristone, a glucocorticoid receptor antagonist indicated for the treatment of
patients with CS.
Methods: We conducted a pooled safety analysis of five phase 3, placebo-controlled clinical trials of
normocortisolemic adults without CS but diagnosed with psychotic depression (n = 1460). Patients were
treated with once-daily mifepristone 300 mg (n = 110), 600 mg (n = 471), or 1200 mg (n = 252), or placebo
(n = 627) administered for 7 consecutive days. All study investigators were trained and instructed to
assess for the development of AI and to report all adverse events (AEs) at each clinic visit. The incidence of
(1) AI or similar terminologies and that of (2) $3 concurrent symptoms that could be associated with
AI was evaluated.
Results: Mean serum cortisol and adrenocorticotropic hormone levels increased dose dependently with
mifepristone treatment. There were no reports of AI and no significant differences between the
mifepristone-treated and placebo groups in the incidence of patients having $3 AEs that could be
associated with AI.
Conclusions: This large pooled analysis of normocortisolemic patients without CS found no cases of AI
and no differences between mifepristone therapy and placebo in the incidence of symptom combinations
mimicking AI, even at the highest (1200 mg) dose. These findings further add clinically important
insights to the safety and tolerability profile of mifepristone therapy.
Copyright © 2017 Endocrine Society
This article is published under the terms of the Creative Commons Attribution-Non Commercial
License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/).
Freeform/Key Words: mifepristone, Cushing syndrome, adrenal insufficiency, adrenal crisis,
safety

The development of adrenal insufficiency (AI), especially acute adrenal crisis, is a major
medical concern following successful surgical treatment of endogenous Cushing syndrome
(CS) and the subsequent attainment of normocortisolemia, and, as such, patients typically
require glucocorticoid replacement therapy until the hypothalamic-pituitary-adrenal (HPA)
axis [Fig. 1(a)] recovers. Effective medical treatment that achieves normocortisolemia in
patients with CS can also increase susceptibility to developing AI, as seen with adrenal
steroidogenesis inhibitors (e.g., ketoconazole, mitotane, metyrapone) [1–4] and drugs that
inhibit adrenocorticotropic hormone (ACTH) secretion (e.g., pasireotide). Assessment of AI
Abbreviations: ACTH, adrenocorticotropic hormone; AE, adverse event; AI, adrenal insufficiency; CS, Cushing syndrome; HPA,
hypothalamic-pituitary-adrenal.
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Figure 1. (a) The HPA axis under normal physiological circumstances regulates the
production of cortisol from the adrenals. Stimulation of the hypothalamus and pituitary to
release CRH and ACTH leads to increased production of cortisol. Excess cortisol in turn
provides inhibitory (negative) feedback at the hypothalamus and pituitary, leading to
decreased release of CRH and ACTH and decreased production of cortisol. (b) In primary AI,
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damage to the adrenal glands leads to decreased production of cortisol and aldosterone; CRH
and ACTH are increased due to ongoing production in the hypothalamus and pituitary and
lack of negative feedback. (c) In secondary AI, there is damage to either the hypothalamus or
pituitary, resulting in decreased release of CRH and/or ACTH, which leads to decreased
production of cortisol. Mineralocorticoid (aldosterone) function is preserved. (d) and (e)
Mifepristone competes with cortisol to bind to glucocorticoid receptors. By antagonizing
these receptors in the hypothalamus and pituitary gland, mifepristone interferes with the
feedback mechanism that regulates cortisol production, causing an increase in ACTH, which
stimulates the production of more cortisol. Although excess antagonism of GR receptors can
mimic features of AI, elevated cortisol levels and mineralocorticoid activation make AI
unlikely. CRH, corticotropin-releasing hormone; GR, glucocorticoid receptor; MOA,
mechanism of action; MR, mineralocorticoid receptor.

during medical treatment of CS is performed mainly on a clinical basis, and, when clinically
suspected, may require temporary dose interruption and treatment with glucocorticoid
therapy to prevent progression to adrenal crisis [5].
Primary AI occurs when the adrenal cortex is impaired or destroyed, such as by an infection, bleeding, or autoimmune disease (e.g., Addison disease), and is characterized by signs
of both glucocorticoid and mineralocorticoid deficiency [6] [Fig. 1(b)]. Acute episodes of primary AI leading to adrenal crisis—a life-threatening medical emergency—are associated
with laboratory abnormalities, including hyponatremia, hyperkalemia, and hypoglycemia,
and signs and symptoms, including hypotension, severe weakness, anorexia, acute abdominal
pain, nausea/vomiting, diarrhea, and confusion [7]. Secondary AI occurs when ACTH secretion (pituitary source) or corticotropin-releasing hormone (hypothalamus source) decreases, causing a reduction in adrenal cortisol production [6, 8] [Fig. 1(c)]. Unlike in primary
AI, mineralocorticoid (aldosterone) function is preserved in secondary AI [6]. Therefore, some
of the key electrolyte and clinical abnormalities (e.g., hyperkalemia, hypotension, hypovolemia, postural dizziness, salt craving) associated with mineralocorticoid deficiency are less
likely to occur. The onset of secondary AI is usually more gradual than primary AI [6, 8].
Successful treatment of CS can also cause glucocorticoid withdrawal syndrome, a constellation of nonspecific symptoms typically characterized by nausea, weight loss, decreased
appetite, fatigue, lethargy, and myalgia [5, 9–12].
Mifepristone (Korlym®; Corcept Therapeutics, Menlo Park, CA) is a competitive glucocorticoid receptor antagonist approved by the US Food and Drug Administration for the treatment
of hyperglycemia in patients with endogenous CS who have failed surgery or are not candidates
for surgery [13]. It binds to the glucocorticoid receptor with .10 times the affinity of endogenous
cortisol, while having no affinity for the mineralocorticoid receptor [Fig. 1(d)] [14, 15]. By
competitively antagonizing the glucocorticoid receptor at the level of the hypothalamus and
pituitary gland, mifepristone disrupts the central negative HPA feedback mechanism,
resulting in increased ACTH and, subsequently, cortisol levels. Therefore, efficacy and safety
monitoring must be based on clinical assessment, not by measuring serum cortisol levels.
Some of the signs and symptoms of glucocorticoid withdrawal syndrome, which indicate
effective treatment of CS in patients receiving mifepristone, may overlap with those of AI. In the
phase 3 SEISMIC (Study of the Efficacy and Safety of Mifepristone in the Treatment of Endogenous Cushing Syndrome) trial of mifepristone, two patients were reported as having adrenal insufficiency [16]. In these patients, symptoms of nausea and decreased appetite were
observed, whereas blood pressure, glucose, and potassium levels remained normal [16]. The
patients’ symptoms were managed with temporary drug discontinuation and/or a short duration
of dexamethasone therapy. A post hoc analysis of the most common adverse events (AEs) during
SEISMIC noted that several AEs, including nausea, fatigue, and headache, declined over time
during treatment, despite increases in mifepristone doses, suggesting that these symptoms were
not dose dependent and, instead, were temporary symptoms of glucocorticoid withdrawal, which
should be anticipated during the initial mifepristone dose titration phase of therapy [17]. The
authors thus suggested that it is more appropriate to characterize the reported AI events as
“excessive glucocorticoid receptor antagonism” [Fig. 1(e)] [17]. Further analysis of mifepristone
in patients with CS would help support these findings; however, assessment of safety outcomes
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requires large patient populations, which are difficult to obtain for patients with CS because of
the relative rarity of the disease. Other controlled clinical trials of mifepristone, in patients
without CS, may offer additional insights into its safety profile.
A number of open-label and double-blind clinical studies have been conducted to assess
mifepristone treatment in patients with psychotic depression [18–25]. HPA axis dysregulation, a
feature of psychotic depression [26, 27], has been thought to contribute to its psychotic symptoms
[25]. Five placebo-controlled, phase 3 studies were conducted to assess 7 days of treatment with
the competitive glucocorticoid receptor antagonist, mifepristone, in patients with psychotic
depression [18–22]. Although the differences between treatment groups were of variable significance, results of the published studies found that mifepristone therapy was associated with
more rapid improvement in psychotic symptoms at day 7 vs placebo, and that this improvement
in symptoms was sustained for several weeks posttreatment [18–20]. Therefore, the objective of
this analysis was to retrospectively examine the incidence of AI and symptoms mimicking AI in a
large pooled analysis of these patients treated with mifepristone therapy at daily doses ranging
from 300 mg up to 1200 mg for 7 days.

1. Methods
A. Study Design
Data from five placebo-controlled phase 3 studies evaluating mifepristone therapy in nonacutely stressed patients with psychotic depression were available for pooled analysis. All five
studies used similar study designs and patient populations; details have been previously
published (NCT00637494, NCT00146523, NCT00130676, NCT00128479) [18–22]. Adults
meeting the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, and Text
Revision and Structured Clinical Interview for DSM Disorders criteria for psychotic depression were eligible for enrollment in study centers across the United States and Eastern
Europe. All patients had blood collections to measure serum cortisol and ACTH levels. None of
the patients had clinical or biochemical evidence of CS. The study protocols were approved by
an institutional review board at each study center, and all patients provided written informed
consent before participation.
Patients were randomized in a 1:1 ratio to receive 7 days of double-blind treatment with
mifepristone or placebo. Mifepristone doses varied across studies (300, 600, or 1200 mg per
day), and clinical assessments were made at baseline and at days 7, 14, 28, 42, and 56. The
investigators of these studies were trained and specifically required to clinically assess signs
and symptoms of AI at each study visit and report all AEs, including spontaneous AEs. Blood
samples were collected for determination of serum cortisol and ACTH levels at baseline,
treatment day 7, and during follow-up as specified according to the study protocols. Additional
safety assessments included physical examinations and laboratory assessments.
For this pooled analysis, we conducted a systematic search of the studies’ safety databases for
the incidence of AI using two different search strategies (Fig. 2). The first strategy searched for
patients with AEs using specific AI terminologies (Addisonian crisis, adrenal crisis, adrenal
insufficiency, or hypoadrenalism), and the second strategy searched for patients with $3 concurrent AEs that could be associated with AI (dizziness/dizzy, fatigue, weakness, hypoglycemia,
hypotension, lethargy, malaise, nausea, orthostatic hypotension, syncope, and vomiting).
B. Statistical Analysis
Data from all five phase 3 studies of mifepristone therapy for psychotic depression were
available for statistical analyses. Safety database search results are presented by mifepristone dose group and/or all mifepristone dose groups combined (300 mg + 600 mg +
1200 mg) vs placebo. Baseline characteristics, changes in mean ACTH and serum cortisol, and
AE frequencies are summarized using descriptive statistics. Differences between all mifepristone doses combined and placebo were analyzed using Fisher’s exact test. P ,0.05 defined
statistical significance.
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Figure 2. Search strategy diagram. Investigators were trained and required to specifically
assess for AI at each clinic visit and report all AEs. Search strategies included searching for
AI-related terms (search strategy 1) and concurrent AEs associated with AI (search strategy 2).

2. Results
A. Patient Disposition
The pooled analysis included a total of 1460 patients, 833 who received mifepristone (300 mg,
n = 110; 600 mg, n = 471; 1200 mg, n = 252) and 627 who received placebo. At baseline, there
were no differences in age, male-to-female ratio, body mass index, or systolic or diastolic blood
pressure between the mifepristone-treated and placebo-treated groups (Table 1).
B. Laboratory and Physical Assessments
All patients were normocortisolemic at baseline based on serum cortisol assessments
(Table 1). After 7 days of mifepristone therapy, mean ACTH and serum cortisol levels increased significantly in a dose-dependent manner (Fig. 3). Mean sodium levels were maintained (140.4 mEq/L) and potassium levels decreased slightly (by ,0.2 to 4.04 mEq/L)
following 7 days of mifepristone therapy. Sodium and potassium levels remained relatively unchanged in the placebo group. Mean 6 standard deviation systolic/diastolic blood
pressure remained stable on day 7 for the mifepristone (123.5 6 12.2/78.2 6 7.9 mm Hg) and
placebo groups (123.3 6 12.9/78.4 6 8.6 mm Hg).
C. Adverse Events
AEs from all five studies (n = 1460) were evaluated by dose group and by all doses combined vs
placebo. Treatment-emergent AEs were reported in 556/833 (66.7%) of mifepristone-treated
patients and 386/627 (61.6%) of placebo-treated patients (Table 2). The AE profile was
comparable between mifepristone and placebo groups, with similar numbers of events noted
in the two groups (Table 2).
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Table 1. Baseline Characteristics of Study Participants

Age (y)
Gender (% female)
ACTH (pg/mL)
Serum cortisol (mg/dL)
BMI (kg/m2)
Systolic BP (mm Hg)
Diastolic BP (mm Hg)
Potassium (mEq/L)
Sodium (mEq/L)

Mifepristone (n = 833)

Placebo (n = 627)

44.7 6 11.6
57.9
n = 778
19.6 6 12.5
n = 807
12.1 6 5.4
n = 534
28.8 6 5.2
122.6 6 12.9
78.2 6 8.7
n = 776
4.2 6 0.4
n = 777
140.4 6 2.9

44.7 6 11.2
60.5
n = 572
22.5 6 15.1
n = 601
12.4 6 5.4
n = 370
28.7 6 5.8
123.4 6 13.9
78.7 6 9.4
n = 603
4.3 6 0.4
n = 607
140.7 6 2.8

Data are mean 6 standard deviation unless stated otherwise. To convert the values for ACTH to picomoles per liter,
multiply by 0.22. To convert the values for serum cortisol to nanomoles per liter, multiply by 27.6.
Abbreviations: BMI, body mass index; BP, blood pressure.

In addition, no events of AI or similar terminologies (search strategy 1) were reported in
any mifepristone-treated groups (Fig. 2). Analysis of patients with $3 concurrent AEs that
potentially could be associated with AI (search strategy 2) revealed no statistically significant
differences between the placebo-treated group vs mifepristone, with only a few affected
patients in either of these groups (Fig. 2; Table 3).

(a)

(b)

Figure 3. (a) Change in mean ACTH after 7 days; (b) Change in mean serum cortisol after 7
days. To convert the values for ACTH to picomoles per liter, multiply by 0.22. To convert the
values for serum cortisol to nanomoles per liter, multiply by 27.6. Mife, mifepristone.
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Among the 252 normocortisolemic patients in this analysis who received the highest dose
(1200 mg) of mifepristone, there were no patients who reported $3 concurrent AEs associated
with possible AI, and the frequency of AEs was similar to that in the placebo group.

3. Discussion
This pooled analysis of normocortisolemic patients without CS found no cases of AI or similar
terminologies and no differences between escalating mifepristone dose groups and placebo in
the incidence of symptom combinations mimicking AI. Mean ACTH and serum cortisol levels
increased significantly during treatment in a dose-dependent manner, indicating adequate
glucocorticoid receptor binding.
The overall frequency of AEs was high in the placebo group; however, this was to
be expected, given the patient population and the protocol, which specified the proactive
solicitation of AEs in addition to spontaneously recorded events. Assessments of AEs by
solicitation in clinical studies have been associated with higher rates of AEs compared with
unstructured (spontaneous) AE assessments [28].
In patients with CS, surgery and effective medical treatment with adrenal steroidogenesis
or ACTH synthesis inhibitors may increase the predisposition to AI and/or glucocorticoid
withdrawal syndrome. Mifepristone, an effective medical treatment of patients with CS [16],
is a competitive glucocorticoid receptor antagonist [14]. Because patients with CS have
established physical dependence/tolerance on supraphysiological glucocorticoid levels, receptor antagonism with mifepristone can be expected to produce symptoms of glucocorticoid
withdrawal. However, with no affinity for the mineralocorticoid receptor, hypotension and
hyperkalemia are unlikely to be observed with mifepristone therapy. In fact, over time, the
excess cortisol created by the perturbation of the negative feedback mechanism in the HPA
axis may activate mineralocorticoid receptors.
During treatment with mifepristone in patients with CS, it is important to monitor glucose
and blood pressure soon after the start of mifepristone treatment because a reduction in
concomitant antidiabetic medications (especially insulin) and/or antihypertensive medications

Table 2. AEs With Frequency of ‡5% in Mifepristone Studies in Patients With Psychotic Depression
(n = 1460)
Mifepristone

Adverse Event (%)
Subjects with $1 TEAE
Nausea
Headache
Insomnia
Constipation
Dizziness
Dry mouth
Diarrhea
Somnolence
Anxiety
Fatigue
Dyspepsia
Back pain
Vomiting
Rash

300 mg
(n = 110)

600 mg
(n = 471)

1200 mg
(n = 252)

All Doses
(n = 833)

Placebo
(n = 627)

66.4
18.2
18.2
3.6
2.7
8.2
4.5
9.1
7.3
5.5
8.2
1.8
6.4
4.5
0.9

62.2
14.0
9.3
5.7
4.2
6.6
5.1
4.0
2.8
3.0
3.6
2.1
1.7
3.8
1.7

75.4
17.5
23.8
5.2
9.5
11.5
11.5
9.1
3.2
5.2
5.6
9.5
2.8
7.5
5.2

66.7
15.6
14.9
5.3
5.6
8.3
7.0
6.2
3.5
4.0
4.8
4.3
2.6
5.0
2.6

61.6
11.2
11.6
6.2
5.7
5.4
5.4
5.1
3.8
3.7
3.3
3.2
2.7
2.6
1.9

Multiple AEs for specific AE preferred terms are counted only once for each patient. AEs are listed by highest
percentage order in last column. Preferred term is listed if a frequency of at least 5% in any column is calculated.
Abbreviation: TEAE, treatment-emergent adverse event.
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Table 3. Patients With ‡3 Concurrent AEs Potentially Associated With Adrenal Insufficiency

3 Concurrent AEsa
4 Concurrent AEsa
Totala

Mifepristone (n = 833)

Placebo (n = 627)

4 (0.48)
0
4 (0.48)

0
1 (0.16)
1 (0.16)

No significant differences (P ,0.05) in AEs were noted between mifepristone and placebo groups, as assessed using
Fisher’s exact test.

a

may be required to prevent hypoglycemia and/or hypotension as the core etiology of their CS is
being treated [17].
The findings from this pooled analysis provide additional insights into the safety/
tolerability of mifepristone. Although the generalizability of these results to other patient
populations, including patients with CS, is uncertain, the pooled patient population in this
analysis was large, increasing the likelihood of discovering rare AEs associated with mifepristone. In addition, the trials included in the pooled analysis were all placebo controlled,
another strength of the analysis. In contrast, despite the large number of patients who received the highest dose of mifepristone, the treatment duration of 7 days may not have been
long enough for signs and symptoms of AI to develop and could be considered a limitation to
the study. Another potential limitation of the study is that the HPA axis of the patients was
not formally evaluated using a Cosyntropin or insulin tolerance test because performing these
tests would have been challenging in such a large cohort and was not one of the objectives of
these studies. Therefore, cortisol collection times differed somewhat among studies, with the
majority of samples collected outside of the morning hours (7:00 AM to 10:00 AM). Despite these
limitations, patients in this analysis had mean baseline serum cortisol levels of 12.2 6 5.4 mg/dL;
thus, it is very unlikely that patients with undiagnosed AI or CS were included in the
analysis of this study. Furthermore, several publications of prospective, double-blind, randomized, placebo-controlled studies of mifepristone administered in healthy (non-CS subjects) populations at dosages of 600 mg daily for 14 to 28 days also did not note any AI events,
which support the findings of the current analysis [29–31].
The lack of AI and the low incidence of symptom combinations mimicking AI with the escalating doses of mifepristone in this study are clinically important, especially as improved
glucose tolerance [16] and progressive global clinical improvement [17, 32] have been observed
with dose escalations of the drug in patients with CS. Furthermore, a recent follow-up analysis of
clinical trial data of patients with CS treated with mifepristone at an average daily dose of 758 6
290 mg found clinically meaningful weight loss ($5% of body weight) that was achieved after
24 weeks of therapy, and this weight loss persisted for ~2 additional years with continued
mifepristone therapy [33]. More recently, a case report was published that described the use of
mifepristone to restore the HPA axis in a woman with prolonged secondary AI following unilateral adrenalectomy [34]. In this case, the patient’s HPA axis failed to recover after 6 years, and
she required maintenance glucocorticoids throughout this time. Multiple attempts to decrease
the dosage of replacement glucocorticoid failed. The patient was started on a very low dose of
mifepristone (150 mg 3 times per week), which was gradually titrated up to 600 mg daily, all while
continuing the same dose of glucocorticoid replacement. Recovery of the HPA axis was biochemically observed (increases in ACTH and cortisol), with both hydrocortisone and mifepristone
doses gradually tapered and discontinued after 8 months of treatment. Remarkably, the patient
did not experience any side effects related to glucocorticoid withdrawal or AI, which the authors
proposed may have been related to the measured titration schedule of mifepristone [34]. Together
these data are reassuring; however, given the limitations of the current analysis, we caution that
clinicians treating patients with CS should still continue to carefully monitor for clinical signs and
symptoms of glucocorticoid withdrawal during mifepristone treatment and, when necessary,
consider treatment of excessive glucocorticoid receptor antagonism with temporary withdrawal
of mifepristone and, if needed, a stress dose with short-term dexamethasone therapy [35].
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In summary, this large pooled analysis of controlled phase 3 trials found no cases of AI or
similar terminologies and no significant differences compared with placebo in the incidence of
symptom combinations mimicking AI during mifepristone treatment in nonacutely stressed
normocortisolemic patients with psychotic depression. Together, these data further substantiate the overall safety and tolerability of mifepristone therapy.
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